136 related articles for article (PubMed ID: 36649216)
21. A single c-Jun N-terminal kinase isoform (JNK3-p54) is an effector in both neuronal differentiation and cell death.
Waetzig V; Herdegen T
J Biol Chem; 2003 Jan; 278(1):567-72. PubMed ID: 12401814
[TBL] [Abstract][Full Text] [Related]
22. Discovery of 3-alkyl-5-aryl-1-pyrimidyl-1
Oh Y; Jang M; Cho H; Yang S; Im D; Moon H; Hah JM
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):372-376. PubMed ID: 31856610
[TBL] [Abstract][Full Text] [Related]
23. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
24. Cerebral ischemia provokes a profound exchange of activated JNK isoforms in brain mitochondria.
Zhao Y; Herdegen T
Mol Cell Neurosci; 2009 Jun; 41(2):186-95. PubMed ID: 19289169
[TBL] [Abstract][Full Text] [Related]
25. The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.
Bogoyevitch MA
Bioessays; 2006 Sep; 28(9):923-34. PubMed ID: 16937364
[TBL] [Abstract][Full Text] [Related]
26. Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration.
Barnat M; Enslen H; Propst F; Davis RJ; Soares S; Nothias F
J Neurosci; 2010 Jun; 30(23):7804-16. PubMed ID: 20534829
[TBL] [Abstract][Full Text] [Related]
27. JNK3 maintains expression of the insulin receptor substrate 2 (IRS2) in insulin-secreting cells: functional consequences for insulin signaling.
Abdelli S; Bonny C
PLoS One; 2012; 7(5):e35997. PubMed ID: 22563476
[TBL] [Abstract][Full Text] [Related]
28. Small peptide inhibitor of JNK3 protects dopaminergic neurons from MPTP induced injury via inhibiting the ASK1-JNK3 signaling pathway.
Pan J; Li H; Zhang B; Xiong R; Zhang Y; Kang WY; Chen W; Zhao ZB; Chen SD
PLoS One; 2015; 10(4):e0119204. PubMed ID: 25856433
[TBL] [Abstract][Full Text] [Related]
29. JNK3 is abundant in insulin-secreting cells and protects against cytokine-induced apoptosis.
Abdelli S; Puyal J; Bielmann C; Buchillier V; Abderrahmani A; Clarke PG; Beckmann JS; Bonny C
Diabetologia; 2009 Sep; 52(9):1871-80. PubMed ID: 19609503
[TBL] [Abstract][Full Text] [Related]
30. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods.
Tuffaha GO; Hatmal MM; Taha MO
J Mol Graph Model; 2019 Sep; 91():30-51. PubMed ID: 31158642
[TBL] [Abstract][Full Text] [Related]
31. Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors.
Dou X; Huang H; Jiang L; Zhu G; Jin H; Jiao N; Zhang L; Liu Z; Zhang L
Eur J Med Chem; 2020 Sep; 201():112445. PubMed ID: 32603981
[TBL] [Abstract][Full Text] [Related]
32. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of 1-aryl-5-anilinoindazoles as c-Jun N-terminal kinase inhibitors.
Jiang R; Frackowiak B; Shin Y; Song X; Chen W; Lin L; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2013 May; 23(9):2683-7. PubMed ID: 23518277
[TBL] [Abstract][Full Text] [Related]
34. JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death.
Choi WS; Abel G; Klintworth H; Flavell RA; Xia Z
J Neuropathol Exp Neurol; 2010 May; 69(5):511-20. PubMed ID: 20418776
[TBL] [Abstract][Full Text] [Related]
35. Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.
Gong L; Han X; Silva T; Tan YC; Goyal B; Tivitmahaisoon P; Trejo A; Palmer W; Hogg H; Jahagir A; Alam M; Wagner P; Stein K; Filonova L; Loe B; Makra F; Rotstein D; Rapatova L; Dunn J; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Hermann J; Kuglstatter A; Goldstein D
Bioorg Med Chem Lett; 2013 Jun; 23(12):3565-9. PubMed ID: 23664880
[TBL] [Abstract][Full Text] [Related]
36. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.
Pan J; Wang G; Yang HQ; Hong Z; Xiao Q; Ren RJ; Zhou HY; Bai L; Chen SD
Mol Pharmacol; 2007 Dec; 72(6):1607-18. PubMed ID: 17855652
[TBL] [Abstract][Full Text] [Related]
37. Arrestin-dependent activation of JNK family kinases.
Zhan X; Kook S; Gurevich EV; Gurevich VV
Handb Exp Pharmacol; 2014; 219():259-80. PubMed ID: 24292834
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of ischemia and reperfusion on c-Jun N-terminal kinase isoform protein and activity.
Shackelford DA; Yeh RY
Brain Res Mol Brain Res; 2001 Oct; 94(1-2):178-92. PubMed ID: 11597778
[TBL] [Abstract][Full Text] [Related]
39. JNK3 contributes to c-Jun activation and apoptosis but not oxidative stress in nerve growth factor-deprived sympathetic neurons.
Bruckner SR; Tammariello SP; Kuan CY; Flavell RA; Rakic P; Estus S
J Neurochem; 2001 Jul; 78(2):298-303. PubMed ID: 11461965
[TBL] [Abstract][Full Text] [Related]
40. Palmitoylation couples the kinases DLK and JNK3 to facilitate prodegenerative axon-to-soma signaling.
Niu J; Holland SM; Ketschek A; Collura KM; Hesketh NL; Hayashi T; Gallo G; Thomas GM
Sci Signal; 2022 Mar; 15(727):eabh2674. PubMed ID: 35349303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
